Halberd (Halberd) Net Margin % : -15,133.33% (As of Jul. 2023)

View and export this data going back to 2009. Start your Free Trial

What is Halberd Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Halberd's Net Income for the six months ended in Jul. 2023 was $-0.45 Mil. Halberd's Revenue for the six months ended in Jul. 2023 was $0.00 Mil. Therefore, Halberd's net margin for the quarter that ended in Jul. 2023 was -15,133.33%.

The historical rank and industry rank for Halberd's Net Margin % or its related term are showing as below:

HALB' s Net Margin % Range Over the Past 10 Years
Min: -20312.5 Med: -15133.33 Max: -514.29
Current: -15133.33

HALB's Net Margin % is ranked worse than
93.19% of 1028 companies
in the Biotechnology industry
Industry Median: -154.79 vs HALB: -15133.33

Halberd Net Margin % Historical Data

The historical data trend for Halberd's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Halberd Net Margin % Chart

Halberd Annual Data

Trend

Jul08

Jul22

Jul23

Net Margin %

-514.29

-20,312.50

-15,133.33

Halberd Semi-Annual Data
	Jul08	Jul22	Jul23
Net Margin %	-514.29	-20,312.50	-15,133.33

Competitive Comparison of Halberd's Net Margin %

For the Biotechnology subindustry, Halberd's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Halberd's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Halberd's Net Margin % distribution charts can be found below:

* The bar in red indicates where Halberd's Net Margin % falls into.

Halberd Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Halberd's Net Margin for the fiscal year that ended in Jul. 2023 is calculated as

Net Margin	=	Net Income (A: Jul. 2023 )	/	Revenue (A: Jul. 2023 )
	=	-0.454	/	0.003
	=	-15,133.33 %

Halberd's Net Margin for the quarter that ended in Jul. 2023 is calculated as

Net Margin	=	Net Income (Q: Jul. 2023 )	/	Revenue (Q: Jul. 2023 )
	=	-0.454	/	0.003
	=	-15,133.33 %

Halberd (OTCPK:HALB) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Halberd Net Margin % Related Terms

Thank you for viewing the detailed overview of Halberd's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Halberd (Halberd) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Halberd Corp (OTCPK:HALB) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

P.O. Box 25, Jackson Center, PA, USA, 16133

Website

https://www.halberdcorporation.com

Halberd Corp is a research-based biotechnology company seeking to discover and develop medical treatments for a range of diseases. The Company's extracorporeal treatment is designed to treat hard-to-cure blood-borne, neurologic and infectious diseases. The Company's patented methodology removes the appropriate bodily fluid from the patient, in a continuous fashion, like dialysis, or in a batch process, like blood sample testing.

Executives

John Christopher Maddox	director, 10 percent owner, officer: President, COO, Treasurer and, other: Interim CFO	10755 VERNON, HUNTINGTON WOODS MI 48070
Mark Sven Lundquist	director, 10 percent owner, officer: CEO, Secretary and Director	24655 TUDOR LANE, FRANKLIN MI 48025
Cocco Nicholas A. Jr.	director	50104 N. JIMMY COURT, CHESTERFIELD MI 48047-1898
Leland Michael Thomas	director	280 LASALLE PLACE, GROSSE POINTE FARMS MI 88236